How Lung-RADS Turns a Lung Nodule Into a Management Plan

A Lung-RADS score is a radiologist's structured translation of a pulmonary nodule into an estimated probability of cancer and a matching next step. Built by the American College of Radiology for low-dose CT lung cancer screening, it sorts every finding into categories from 0 to 4X, where a higher number signals a higher chance of malignancy and a more urgent workup. The 2022 revision refined how a few difficult findings are handled and clarified what counts as growth, so two radiologists reading the same scan are more likely to reach the same recommendation. The point is consistency: the same nodule should produce the same plan regardless of who reads it.

From a spot on a scan to a next step

Lung cancer screening produces a lot of nodules, and most of them are harmless. Without a shared grammar, the same 7 mm spot might earn a repeat scan from one radiologist and a biopsy referral from another. Lung-RADS supplies that grammar. It ties each category to a rough probability of malignancy and a specific management action, so the report a patient's clinician receives already carries an implied plan rather than an open question. Categories 1 and 2 are negative screens; categories 3 and 4 are positive and trigger closer follow-up.

The system also encodes nodule type, because behavior differs by composition. Solid nodules, part-solid nodules with both a solid and a hazy component, and non-solid (ground-glass) nodules each carry their own size thresholds. Size is measured as the mean of long and short axis on the same image, and that measurement, together with whether a nodule is new or growing, drives the category.

Reading the categories as a risk ladder

Categories 1 and 2: the quiet majority

Category 1 means no nodules of concern; category 2 covers findings with benign appearance or behavior, such as a solid nodule under 6 mm at baseline or a stable non-solid nodule. Both carry an estimated malignancy probability under 1 percent, and both return the patient to routine annual screening. Together these two categories account for roughly 90 percent of screens, which is the practical reason the system exists: it lets the large benign majority pass through quickly so attention concentrates on the few findings that matter.

Category 3: watchful waiting with a clock

Category 3 is "probably benign," with an estimated malignancy probability of 1 to 2 percent. It captures solid nodules from 6 to under 8 mm at baseline, new solid nodules from 4 to under 6 mm, and certain part-solid or larger ground-glass nodules. The recommended action is a repeat low-dose CT in 6 months rather than immediate intervention. The logic is that short-interval imaging separates the indolent from the growing at low cost and without a needle.

Category 4: suspicion that earns a workup

Category 4 splits by degree. Category 4A (estimated 5 to 15 percent malignancy) covers solid nodules from 8 to under 15 mm and prompts a 3-month CT, sometimes PET/CT once a solid component reaches 8 mm. Category 4B (over 15 percent) covers solid nodules 15 mm or larger and sends the patient toward diagnostic CT, PET/CT, or tissue sampling. Category 4X is a judgment override: a nodule that would otherwise be category 3 or 4 but carries extra worrying features, such as spiculated margins or associated lymph node enlargement, gets elevated to the highest-suspicion tier. That override is where a radiologist's pattern recognition is allowed to outrank the size table.

What the 2022 update actually changed

The 2022 version did not rewrite the ladder; it patched the places where the earlier rules were ambiguous. It added explicit handling for atypical pulmonary cysts, the thick-walled or multilocular cystic lesions that can harbor cancer, placing suspicious ones in category 4A or 4B. It gave juxtapleural nodules their own rule, so that small, smooth, triangular nodules sitting against the pleura, usually benign intrapulmonary lymph nodes, are read as category 2 rather than pushed into follow-up. It classified airway-centered nodules by location, and it added guidance for findings that look infectious or inflammatory.

Two changes matter most for consistency. The update clarified how to determine whether a nodule has grown, applying the threshold of an increase of more than 1.5 mm in mean diameter so that two readers judge a "bigger" nodule the same way. And it introduced stepped management for nodules that stay stable or shrink over successive exams. The RadioGraphics review of v2022 walks through these scenarios in detail, and the ACR's own v2022 statement is the authoritative source for the category definitions.

The evidence behind the trade-offs

Every threshold in Lung-RADS is a bet about balancing missed cancers against false alarms, and that balance is not hypothetical. In the National Lung Screening Trial, a large share of people screened by CT had at least one positive result over three annual rounds, and the great majority of those positives turned out to be false alarms. When Pinsky and colleagues retrospectively applied Lung-RADS to that trial in Annals of Internal Medicine, the baseline false-positive rate fell from 26.6 percent to 12.8 percent, and the post-baseline rate fell from 21.8 percent to 5.3 percent. Sensitivity also dropped, from 93.5 to 84.9 percent at baseline, which is the honest cost: raising size thresholds to spare people needless biopsies means a small number of early cancers are watched rather than worked up right away. Each version's adjustments, including the 2022 changes, try to nudge that trade-off without giving up the mortality benefit that justified screening in the first place. That benefit, and the eligibility criteria behind it, underpin the U.S. Preventive Services Task Force recommendation for annual low-dose CT in high-risk adults.

What the score is, and what it is not

A Lung-RADS category is a probability statement and a suggested pathway, not a diagnosis. It describes a nodule at one moment against population data; it does not know an individual's full history, and its numbers are estimates that particular patients can sit above or below. A category 4 result is not a cancer verdict, and a category 2 is not a guarantee. This article is educational and not medical advice; screening and follow-up decisions belong to a patient and their own clinicians, who weigh the score alongside everything the score cannot see.